More kidney hope
For First Time, Pig Kidneys Provide Life-Sustaining Organ Function in Human: Hope for 100,000 on Donor List
For First Time, Pig Kidneys Provide Life-Sustaining Organ Function in Human: Hope for 100,000 on Donor List
For the first time, genetically modified pig kidneys provided “life-sustaining kidney function” during the course of a planned seven-day clinical study—a first step in addressing the critical crisis worldwide of kidney donor organ shortage.
The University of Alabama’s pre-clinical human study at Birmingham also advances the science and promise of xenotransplantation as a therapy to potentially cure end-stage kidney disease—just as a human-to-human transplants can.
“It has been truly extraordinary to see the first-ever preclinical demonstration that appropriately modified pig kidneys can provide normal, life-sustaining kidney function in a human safely and be achieved using a standard immunosuppression regimen,” said UAB transplant surgeon scientist Jayme Locke, M.D., director of UAB’s Comprehensive Transplant Institute and lead author of the paper.
“The kidneys functioned remarkably over the course of this seven-day study,” she said. “We were able to gather additional safety and scientific information critical to our efforts to seek FDA clearance of a Phase I clinical trial in living humans and hopefully add a new, desperately needed solution to address an organ shortage crisis responsible for tens of thousands of preventable deaths each year.”
The peer-reviewed findings published last month in JAMA Surgery describes the pioneering pre-clinical human research performed on a recipient experiencing brain death by the Locke and Heersink School of Medicine team. It comes 19 months after last year’s groundbreaking peer reviewed UAB xenotransplant study in which genetically modified pig kidneys were successfully transplanted into a recipient after brain death.
The University of Alabama’s pre-clinical human study at Birmingham also advances the science and promise of xenotransplantation as a therapy to potentially cure end-stage kidney disease—just as a human-to-human transplants can.
“It has been truly extraordinary to see the first-ever preclinical demonstration that appropriately modified pig kidneys can provide normal, life-sustaining kidney function in a human safely and be achieved using a standard immunosuppression regimen,” said UAB transplant surgeon scientist Jayme Locke, M.D., director of UAB’s Comprehensive Transplant Institute and lead author of the paper.
“The kidneys functioned remarkably over the course of this seven-day study,” she said. “We were able to gather additional safety and scientific information critical to our efforts to seek FDA clearance of a Phase I clinical trial in living humans and hopefully add a new, desperately needed solution to address an organ shortage crisis responsible for tens of thousands of preventable deaths each year.”
The peer-reviewed findings published last month in JAMA Surgery describes the pioneering pre-clinical human research performed on a recipient experiencing brain death by the Locke and Heersink School of Medicine team. It comes 19 months after last year’s groundbreaking peer reviewed UAB xenotransplant study in which genetically modified pig kidneys were successfully transplanted into a recipient after brain death.
Comment